Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Combined with Chemoimmunotherapy in Biliary Tract Cancer
ChiCTR2500114269Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Dec 2025
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bortezomib in biliary cancer (2 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Progression-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
bortezomib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2500114269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114269.